View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGeNeuro 배당 및 자사주 매입배당 기준 점검 0/6GeNeuro 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • May 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2023 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-€14m). Revenue is less than US$1m. Market cap is less than US$10m (€1.91m market cap, or US$2.16m).New Risk • Nov 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-€14m). Earnings have declined by 8.6% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€1.92m market cap, or US$2.03m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).Price Target Changed • Jul 02Price target decreased by 49% to €2.05Down from €4.00, the current price target is an average from 2 analysts. New target price is 791% above last closing price of €0.23. Stock is down 86% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.59 last year.공고 • Jun 28GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 SyndromeGeNeuro SA announced the GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric diseases, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications. Preliminary analyses suggest that shorter disease duration at time of inclusion, as well as the evolution of the underlying HERV-W ENV status, may have an impact on the efficacy outcome measures. The Company will continue to analyze complete results once they become available, including additional biomarkers. GeNeuro thanks all the study participants, the investigators and all other site personnel for their commitment that made this novel study possible. The learnings from this study will certainly advance the knowledge of this new disease affecting millions of persons worldwide.공고 • May 18GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024GeNeuro SA announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study. The trial "Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome" (GNC-501) is a randomized, placebo-controlled, biomarker-based, Phase 2 clinical trial assessing the safety and the efficacy of the treatment with temelimab, a monoclonal antibody neutralizing the pathogenic HERV-W ENV protein. The trial has recruited 203 patients across 14 clinical centres in Switzerland, Spain and Italy. All patients included in the study were tested positive for the expression of the HERV W-ENV protein, which is a key factor in the activation of the innate immune response and is suspected to have a major role in the persistence of inflammation and in the broad spectrum of neurological symptoms affecting patients with post-COVID. Over 1/3 of the patients screened had detectable W-ENV protein expression in blood, suggesting that temelimab could become a relevant treatment option for a large subset of this underserved patient population. All enrolled patients received 6 intravenous infusions of temelimab or placebo (1 to 1 randomization) over 24 weeks. The clinical endpoints will assess the efficacy and the safety of the treatment with temelIMab on the improvement in fatigue and cognitive impairment measures.공고 • Mar 21Geneuro SA Announces Appointments of Board of DirectorsGeNeuro SA at its Extraordinary General Meeting (EGM) of March 18, 2024, approved election of two new Members of the Board of Directors, Mrs. Sandrine Flory, Chief Financial Officer of Institut Mérieux, and Mr. Pascal Lemaire, Chief Financial Officer of Servier.New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.5m). Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€13m net loss in 2 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (€32.6m market cap, or US$35.1m).공고 • Feb 02GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,666,901 Price\Range: €1.05 Transaction Features: Subsequent Direct Listing공고 • Dec 11Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without ModificationsGeNeuro announced that, as planned in the Study Protocol, the Independent Data Monitoring Committee met to review the unblinded safety and efficacy data of the first 90 patients after three months of treatment. Based on the planned interim analysis of efficacy and safety data, which included an analysis for futility, the IDMC recommended to "continue the trial without any modifications". The study "Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome" is a randomized, placebo-controlled, biomarker-based Phase 2 clinical trial evaluating the effect of temelimab treatment on the clinical course of these symptoms. This trial enrolled 203 patients in 14 clinical centers in Switzerland, Spain and Italy, who were affected by neurological syndromes post-COVID, and who tested positive to the presence of W-ENV in their blood. W-ENV is expected to have a major role in the persistence of inflammation and in the neurological symptoms affecting these patients, and temelimab is a highly specific neutralizing anti-W-ENV-antibody. GeNeuro's precision medicine approach allows to identify, within the millions of patients affected by long-COVID, those for whom the treatment may be relevant. Results are expected in June 2024.New Risk • Dec 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€5.5m). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€15m). Currently unprofitable and not forecast to become profitable over next 2 years (€13m net loss in 2 years). Market cap is less than US$100m (€26.1m market cap, or US$28.1m).Breakeven Date Change • Dec 08Forecast to breakeven in 2024The analyst covering GeNeuro expects the company to break even for the first time. New forecast suggests losses will reduce by 20% to 2023. The company is expected to make a profit of €1.10m in 2024.공고 • Nov 29GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024GeNeuro announced the completion of the recruitment of its Phase 2 trial evaluating temelimab against long-COVID. The trial “Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome” is a randomized, placebo-controlled, biomarker-based, Phase 2 clinical trial assessing the effect of the treatment with temelimab on the clinical course of these symptoms. The trial has recruited 203 patients across 14 clinical centres in Switzerland, Spain and Italy. All enrolled patients receive 6 intravenous infusions of temelimab or placebo (1 to 1 randomization) over 24 weeks. The clinical endpoints will assess the efficacy and the safety of the treatment with temelimab on the improvement in fatigue and cognitive impairment measures. The recruitment of the trial has already demonstrated that the expression of the pathogenic W-ENV protein, triggered by the SARS-CoV-2 infection, may continue long after the acute phase has been resolved. Over one third of the patients presenting long-COVID syndromes who were screened were positive to the presence of W-ENV in their blood. W-ENV is suspected to have a major role in the persistence of inflammation and in the neurological symptoms affecting these patients, and temelimab is a highly specific neutralizing anti-W-ENV-antibody. GeNeuro’s precision medicine approach allows to identify, within the millions of patients affected by long-COVID, those for whom the treatment may be relevant. The development of temelimab (GNbAC1) is the result of more than 25 years of research into human endogenous retroviruses (HERVs), including 15 years within Institut Mérieux and INSERM before GeNeuro was founded in 2006. HERVs have been incorporated into the human genome during the evolution of mankind and typically remain “silent genes”, but may be activated under certain conditions and were found to be involved in the development of auto-immune diseases. The viral envelope protein encoded by the HERV-W family (W-ENV) has been found to be pro-inflammatory and pathogenic to nervous system cells. W-ENV is found in the brains of MS patients, and particularly in active lesions. In two Phase II multiple sclerosis trials Temelimab has shown promising results on MRI features and liquid biomarkers related to neurodegenerative processes such as brain atrophy. Temelimab is a neutralizing anti-W-ENV-antibody; by this capacity it simultaneously blocks inflammatory and neurodegenerative processes. Given that W-ENV has no known physiological function, temelimab has demonstrated a good safety and tolerability profile in the current study, with no effect on the patient’s immune system, which bears out the profile observed in all clinical trials carried out to date.New Risk • Oct 20New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€5.5m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€5.5m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (€9.5m net loss next year). Market cap is less than US$100m (€38.0m market cap, or US$40.3m).New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (€9.5m net loss next year). Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (€32.6m market cap, or US$34.2m).공고 • Sep 12GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic PatientsGeNeuro SA announced, in collaboration with Professor Marion Leboyer from the FondaMental Foundation, and Dr Ryad Tamouza, head immunologist for the immuno-psychiatry team, the publication in the leading scientific publication Translational Psychiatry of a new study showing that over 80% of the patients hospitalized in a psychiatry department near Paris during the first wave of the COVID-19 pandemic had been exposed to SARS-CoV-2, i.e., 1.6 times more than for the control group. 27% of patients with non-vaccinal SARS-COV-2 positive serology corresponded to the previously described mental disorder subgroup associating HERV-W expression. These results are confronted to those of a recent study has shown showing that the SARS-CoV- 2 virus causing COVID-19 can trigger the activation of the HERV-Wretrovirus, which may result in post-infectious syndromes or diseases associated with persistent HERV-W ENV expression in genetically predisposed individuals. Several specific factors explaining asymptomatic or unrecorded COVID-19 in these in-patients, hospitalized in the Psychiatry Department of the Creteil-Paris VII university hospital in France have also been suggested. The authors conclude that this now well defined subgroup of inflammatory psychoses calls for the development of a differential therapeutic approach in psychoses and more specifically through the identification and development of further HERV-related precision medicine therapies. Preliminary results of this study were presented in 2022 at the Schizophrenia International Research Society (SIRS) Conference, in Florence, Italy, in the dedicated session on HERVs and psychoses chaired by Prof. Robert Yolken (Johns Hopkins University, Baltimore, USA).공고 • Jul 26GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023GeNeuro SA announced that they will report first half, 2023 results on Sep 29, 2023New Risk • Jul 07New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €12m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Market cap is less than US$100m (€41.8m market cap, or US$45.8m).Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Philippe Archinard was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • May 25GeNeuro SA, Annual General Meeting, Jun 14, 2023GeNeuro SA, Annual General Meeting, Jun 14, 2023, at 15:00 Central European Standard Time. Location: head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates Geneva SwitzerlandPrice Target Changed • Nov 16Price target decreased to €5.55Down from €6.55, the current price target is an average from 2 analysts. New target price is 243% above last closing price of €1.62. Stock is down 57% over the past year. The company is forecast to post a net loss per share of €0.88 next year compared to a net loss per share of €0.32 last year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Hedi Ben Brahim was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 27Price target decreased to €5.55Down from €6.55, the current price target is provided by 1 analyst. New target price is 83% above last closing price of €3.04. Stock is down 40% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €0.32 last year.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Hedi Ben Brahim was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Jun 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.73 to -€0.17 per share. Revenue forecast unchanged from €10.4m at last update. Biotechs industry in France expected to see average net income growth of 0.07% next year. Consensus price target of €6.55 unchanged from last update. Share price was steady at €3.66 over the past week.분석 기사 • Mar 14Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)GeNeuro SA ( EPA:GNRO ) is possibly approaching a major achievement in its business, so we would like to shine some...Is New 90 Day High Low • Jan 26New 90-day high: €3.92The company is up 46% from its price of €2.69 on 28 October 2020. The French market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 46% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: €2.60The company is down 18% from its price of €3.18 on 24 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 32% over the same period.분석 기사 • Nov 28Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before LongWe feel now is a pretty good time to analyse GeNeuro SA's (EPA:GNRO) business as it appears the company may be on the...Is New 90 Day High Low • Nov 10New 90-day low: €2.62The company is down 16% from its price of €3.13 on 11 August 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: €3.00The company is down 14% from its price of €3.48 on 23 July 2020. The French market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Oct 05New 90-day low: €3.01The company is down 19% from its price of €3.70 on 07 July 2020. The French market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GNRO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GNRO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장GeNeuro 배당 수익률 vs 시장GNRO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GNRO)n/a시장 하위 25% (FR)2.0%시장 상위 25% (FR)5.3%업계 평균 (Biotechs)2.3%분석가 예측 (GNRO) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GNRO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GNRO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GNRO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GNRO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YFR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 04:57종가2026/05/11 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GeNeuro SA는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Stephanie LefebvreGilbert DupontDelphine Le LouetSociete Generale Cross Asset ResearchEric Le BerrigaudStifel, formerly Bryan Garnier
New Risk • May 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2023 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-€14m). Revenue is less than US$1m. Market cap is less than US$10m (€1.91m market cap, or US$2.16m).
New Risk • Nov 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-€14m). Earnings have declined by 8.6% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€1.92m market cap, or US$2.03m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).
Price Target Changed • Jul 02Price target decreased by 49% to €2.05Down from €4.00, the current price target is an average from 2 analysts. New target price is 791% above last closing price of €0.23. Stock is down 86% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.59 last year.
공고 • Jun 28GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 SyndromeGeNeuro SA announced the GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric diseases, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications. Preliminary analyses suggest that shorter disease duration at time of inclusion, as well as the evolution of the underlying HERV-W ENV status, may have an impact on the efficacy outcome measures. The Company will continue to analyze complete results once they become available, including additional biomarkers. GeNeuro thanks all the study participants, the investigators and all other site personnel for their commitment that made this novel study possible. The learnings from this study will certainly advance the knowledge of this new disease affecting millions of persons worldwide.
공고 • May 18GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024GeNeuro SA announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study. The trial "Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome" (GNC-501) is a randomized, placebo-controlled, biomarker-based, Phase 2 clinical trial assessing the safety and the efficacy of the treatment with temelimab, a monoclonal antibody neutralizing the pathogenic HERV-W ENV protein. The trial has recruited 203 patients across 14 clinical centres in Switzerland, Spain and Italy. All patients included in the study were tested positive for the expression of the HERV W-ENV protein, which is a key factor in the activation of the innate immune response and is suspected to have a major role in the persistence of inflammation and in the broad spectrum of neurological symptoms affecting patients with post-COVID. Over 1/3 of the patients screened had detectable W-ENV protein expression in blood, suggesting that temelimab could become a relevant treatment option for a large subset of this underserved patient population. All enrolled patients received 6 intravenous infusions of temelimab or placebo (1 to 1 randomization) over 24 weeks. The clinical endpoints will assess the efficacy and the safety of the treatment with temelIMab on the improvement in fatigue and cognitive impairment measures.
공고 • Mar 21Geneuro SA Announces Appointments of Board of DirectorsGeNeuro SA at its Extraordinary General Meeting (EGM) of March 18, 2024, approved election of two new Members of the Board of Directors, Mrs. Sandrine Flory, Chief Financial Officer of Institut Mérieux, and Mr. Pascal Lemaire, Chief Financial Officer of Servier.
New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.5m). Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€13m net loss in 2 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (€32.6m market cap, or US$35.1m).
공고 • Feb 02GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,666,901 Price\Range: €1.05 Transaction Features: Subsequent Direct Listing
공고 • Dec 11Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without ModificationsGeNeuro announced that, as planned in the Study Protocol, the Independent Data Monitoring Committee met to review the unblinded safety and efficacy data of the first 90 patients after three months of treatment. Based on the planned interim analysis of efficacy and safety data, which included an analysis for futility, the IDMC recommended to "continue the trial without any modifications". The study "Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome" is a randomized, placebo-controlled, biomarker-based Phase 2 clinical trial evaluating the effect of temelimab treatment on the clinical course of these symptoms. This trial enrolled 203 patients in 14 clinical centers in Switzerland, Spain and Italy, who were affected by neurological syndromes post-COVID, and who tested positive to the presence of W-ENV in their blood. W-ENV is expected to have a major role in the persistence of inflammation and in the neurological symptoms affecting these patients, and temelimab is a highly specific neutralizing anti-W-ENV-antibody. GeNeuro's precision medicine approach allows to identify, within the millions of patients affected by long-COVID, those for whom the treatment may be relevant. Results are expected in June 2024.
New Risk • Dec 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€5.5m). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€15m). Currently unprofitable and not forecast to become profitable over next 2 years (€13m net loss in 2 years). Market cap is less than US$100m (€26.1m market cap, or US$28.1m).
Breakeven Date Change • Dec 08Forecast to breakeven in 2024The analyst covering GeNeuro expects the company to break even for the first time. New forecast suggests losses will reduce by 20% to 2023. The company is expected to make a profit of €1.10m in 2024.
공고 • Nov 29GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024GeNeuro announced the completion of the recruitment of its Phase 2 trial evaluating temelimab against long-COVID. The trial “Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome” is a randomized, placebo-controlled, biomarker-based, Phase 2 clinical trial assessing the effect of the treatment with temelimab on the clinical course of these symptoms. The trial has recruited 203 patients across 14 clinical centres in Switzerland, Spain and Italy. All enrolled patients receive 6 intravenous infusions of temelimab or placebo (1 to 1 randomization) over 24 weeks. The clinical endpoints will assess the efficacy and the safety of the treatment with temelimab on the improvement in fatigue and cognitive impairment measures. The recruitment of the trial has already demonstrated that the expression of the pathogenic W-ENV protein, triggered by the SARS-CoV-2 infection, may continue long after the acute phase has been resolved. Over one third of the patients presenting long-COVID syndromes who were screened were positive to the presence of W-ENV in their blood. W-ENV is suspected to have a major role in the persistence of inflammation and in the neurological symptoms affecting these patients, and temelimab is a highly specific neutralizing anti-W-ENV-antibody. GeNeuro’s precision medicine approach allows to identify, within the millions of patients affected by long-COVID, those for whom the treatment may be relevant. The development of temelimab (GNbAC1) is the result of more than 25 years of research into human endogenous retroviruses (HERVs), including 15 years within Institut Mérieux and INSERM before GeNeuro was founded in 2006. HERVs have been incorporated into the human genome during the evolution of mankind and typically remain “silent genes”, but may be activated under certain conditions and were found to be involved in the development of auto-immune diseases. The viral envelope protein encoded by the HERV-W family (W-ENV) has been found to be pro-inflammatory and pathogenic to nervous system cells. W-ENV is found in the brains of MS patients, and particularly in active lesions. In two Phase II multiple sclerosis trials Temelimab has shown promising results on MRI features and liquid biomarkers related to neurodegenerative processes such as brain atrophy. Temelimab is a neutralizing anti-W-ENV-antibody; by this capacity it simultaneously blocks inflammatory and neurodegenerative processes. Given that W-ENV has no known physiological function, temelimab has demonstrated a good safety and tolerability profile in the current study, with no effect on the patient’s immune system, which bears out the profile observed in all clinical trials carried out to date.
New Risk • Oct 20New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€5.5m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€5.5m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (€9.5m net loss next year). Market cap is less than US$100m (€38.0m market cap, or US$40.3m).
New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (€9.5m net loss next year). Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (€32.6m market cap, or US$34.2m).
공고 • Sep 12GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic PatientsGeNeuro SA announced, in collaboration with Professor Marion Leboyer from the FondaMental Foundation, and Dr Ryad Tamouza, head immunologist for the immuno-psychiatry team, the publication in the leading scientific publication Translational Psychiatry of a new study showing that over 80% of the patients hospitalized in a psychiatry department near Paris during the first wave of the COVID-19 pandemic had been exposed to SARS-CoV-2, i.e., 1.6 times more than for the control group. 27% of patients with non-vaccinal SARS-COV-2 positive serology corresponded to the previously described mental disorder subgroup associating HERV-W expression. These results are confronted to those of a recent study has shown showing that the SARS-CoV- 2 virus causing COVID-19 can trigger the activation of the HERV-Wretrovirus, which may result in post-infectious syndromes or diseases associated with persistent HERV-W ENV expression in genetically predisposed individuals. Several specific factors explaining asymptomatic or unrecorded COVID-19 in these in-patients, hospitalized in the Psychiatry Department of the Creteil-Paris VII university hospital in France have also been suggested. The authors conclude that this now well defined subgroup of inflammatory psychoses calls for the development of a differential therapeutic approach in psychoses and more specifically through the identification and development of further HERV-related precision medicine therapies. Preliminary results of this study were presented in 2022 at the Schizophrenia International Research Society (SIRS) Conference, in Florence, Italy, in the dedicated session on HERVs and psychoses chaired by Prof. Robert Yolken (Johns Hopkins University, Baltimore, USA).
공고 • Jul 26GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023GeNeuro SA announced that they will report first half, 2023 results on Sep 29, 2023
New Risk • Jul 07New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €12m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Market cap is less than US$100m (€41.8m market cap, or US$45.8m).
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Philippe Archinard was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • May 25GeNeuro SA, Annual General Meeting, Jun 14, 2023GeNeuro SA, Annual General Meeting, Jun 14, 2023, at 15:00 Central European Standard Time. Location: head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates Geneva Switzerland
Price Target Changed • Nov 16Price target decreased to €5.55Down from €6.55, the current price target is an average from 2 analysts. New target price is 243% above last closing price of €1.62. Stock is down 57% over the past year. The company is forecast to post a net loss per share of €0.88 next year compared to a net loss per share of €0.32 last year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Hedi Ben Brahim was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 27Price target decreased to €5.55Down from €6.55, the current price target is provided by 1 analyst. New target price is 83% above last closing price of €3.04. Stock is down 40% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €0.32 last year.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Hedi Ben Brahim was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Jun 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.73 to -€0.17 per share. Revenue forecast unchanged from €10.4m at last update. Biotechs industry in France expected to see average net income growth of 0.07% next year. Consensus price target of €6.55 unchanged from last update. Share price was steady at €3.66 over the past week.
분석 기사 • Mar 14Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)GeNeuro SA ( EPA:GNRO ) is possibly approaching a major achievement in its business, so we would like to shine some...
Is New 90 Day High Low • Jan 26New 90-day high: €3.92The company is up 46% from its price of €2.69 on 28 October 2020. The French market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 46% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: €2.60The company is down 18% from its price of €3.18 on 24 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 32% over the same period.
분석 기사 • Nov 28Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before LongWe feel now is a pretty good time to analyse GeNeuro SA's (EPA:GNRO) business as it appears the company may be on the...
Is New 90 Day High Low • Nov 10New 90-day low: €2.62The company is down 16% from its price of €3.13 on 11 August 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: €3.00The company is down 14% from its price of €3.48 on 23 July 2020. The French market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Oct 05New 90-day low: €3.01The company is down 19% from its price of €3.70 on 07 July 2020. The French market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.